Percent decrease of serum prostate-specific antigen after dutasteride administration is equivalent in men with clinical benign prostatic hyperplasia having baseline prostate-specific antigen >10 ng/mL and those having baseline prostate-specific antigen 2.5-10 ng/mL

Int J Urol. 2017 Mar;24(3):238-239. doi: 10.1111/iju.13284. Epub 2017 Feb 16.

Authors

Hideki Takeshita¹, Satoru Kawakami^{1

2}, Akihiro Yano¹, Yohei Okada¹, Makoto Morozumi¹, Takumi Yamada¹

Affiliations

¹ Department of Urology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.
² Department of Urology, Harada Hospital, Iruma, Saitama, Japan.

PMID: 28208224
DOI: 10.1111/iju.13284

No abstract available

MeSH terms

5-alpha Reductase Inhibitors / administration & dosage*
Aged
Aged, 80 and over
Dutasteride / administration & dosage*
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Prostate-Specific Antigen / blood*
Prostatic Hyperplasia / diagnostic imaging
Prostatic Hyperplasia / drug therapy*
Retrospective Studies
Severity of Illness Index

Substances

5-alpha Reductase Inhibitors
Prostate-Specific Antigen
Dutasteride